Single-use Bioreactor - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The single-use bioreactor market size is projected to be USD 5.47 billion in 2025, USD 6.28 billion in 2026, and reach USD 13.07 billion by 2031, growing at a CAGR of 15.78% from 2026 to 2031. This report is Segmented by Product Type (Stirred-Tank, Wave-Induced, Fixed-Bed, Orbitally-Shaken & Other SUBs), Volume Range (Less Than 100 L, 100-500 L, and More), Application (Research & Process Development, and More), End-User (Pharmaceutical & Biopharmaceutical Companies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Single-use Bioreactor Market Trends and Insights

Intensifying Shift From Stainless-Steel to Disposable Bioprocessing Systems

Pharmaceutical manufacturers are retiring legacy stainless trains in favor of single-use platforms that remove cleaning validation, lower water use by up to 80%, and cut turnaround cycles from weeks to days. Danaher’s Cytiva division reported resurgent disposable-consumable sales in late 2024, underscoring dependence on bag assemblies and sensors. Sartorius indicated 75% of Bioprocess Solutions revenue stems from consumables, highlighting customer lock-in once validation is complete. Labor costs for steaming and documentation also tilt economics toward pre-sterilized bags in Western markets, although Indian and Chinese biosimilar firms still favor hybrid plants because import tariffs inflate consumable costs.

Rapid Growth of Cell & Gene Therapies Elevating Demand for Flexible Small-Batch Manufacturing

Autologous CAR-T treatments require 50 mL-10 L runs, volumes incompatible with 500 L stainless reactors. Bristol Myers Squibb reserved USD 380 million in capacity with Cellares in 2024 for its automated Cell Shuttle platform that pairs single-use bioreactors with closed cell-processing hardware. FDA approvals for multiple CAR-T constructs in 2024-2025 and the agency’s Advanced Manufacturing Technologies pathway spur decentralized manufacturing near oncology centers. Univercells’ 50 L NevoLine system can be shipped in a container to remote clinics, reinforcing modular deployments.

Leachables & Extractables Compliance Uncertainty

Multilayer polyethylene films may leach plasticizers that delay approvals. FDA and EMA require up to 18 months of studies costing USD 0.5-1 million per assembly. High-potency products heighten risk, prompting some Japanese sponsors to retain stainless tanks for commercial lots.

Other drivers and restraints analyzed in the detailed report include:

• Cost-Saving Potential in Early-Stage Clinical Production
• Accelerated Vaccine Programs Post-COVID-19
• High Recurring Consumable Costs

Segment Analysis

Stirred-tank systems commanded 57.26% of 2025 revenue, reinforcing their role as the workhorse for mammalian cell culture. The single-use bioreactor market size for stirred-tank units is sustained by antibody titers exceeding 5 g/L. Orbitally-shaken vessels are expanding at 18.68% annually on adoption by academic labs, while wave-induced designs serve seed-train and viral-vector work. PBS Biotech’s vertical-wheel approach improves oxygen transfer with lower shear. Thermo Fisher’s sensor-embedded DynaDrive extends digital monitoring into benchtop volumes.

Adoption patterns reflect validation stringency. Commercial antibody makers value historical data from stirred tanks, but early-stage gene therapy teams favor orbitals that fit inside biosafety cabinets. Fixed-bed reactors fill perfusion niches, while the single-use bioreactor industry continues to test hybrid perfusion/fed-batch models that reduce media use.

The 500-2,000 L band represented 43.72% of 2025 revenue and remains the core of CDMO offerings. The single-use bioreactor market share for this range aligns with Phase III batch sizes that yield 5-10 kg per run. Danaher’s 500 L and 2,000 L X-platform models shorten installation to eight weeks, accelerating client onboarding.

Sub-100 L systems are forecast to grow at 19.42% as CAR-T makers and universities deploy benchtop tools. Conversely, designs above 2,000 L face engineering limits; experimental 4,000 L bags remain scarce and expensive, capping growth despite demand for large-scale biosimilars.

Complete Report Scope:

• By Product Type
  • Stirred-Tank SUBs
  • Wave-Induced SUBs
  • Fixed-Bed SUBs
  • Orbitally-Shaken & Other SUBs
• By Volume Range
  • Less than 100 L
  • 100 - 500 L
  • 500 - 2 000 L
  • More than 2,000 L
• By Application
  • Research & Process Development
  • Clinical-Scale Production
  • Commercial-Scale Biopharmaceutical Manufacturing
• By End-User
  • Pharmaceutical & Biopharmaceutical Companies
  • Contract Development & Manufacturing Organisations (CDMOs/CMOs)
  • Academic & Research Institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 36.11% of 2025 revenue, buoyed by U.S. headquarters and an FDA program that expedites advanced manufacturing reviews. Growth is plateauing as capacity saturates, prompting suppliers to pivot to Asia-Pacific, projected to grow at 17.02% through 2031. Thermo Fisher’s 2025 design centers in Singapore and Shanghai reflect this tilt.

Europe ranks second, led by Germany, Switzerland, and the UK, where water-usage rules encourage disposable systems. Merck KGaA’s EUR 300 million Darmstadt hub and Sartorius’ consumable-centric model illustrate the focus on high-margin supplies. Post-Brexit dual approvals add modest complexity, yet mutual recognition eases trade.

Asia-Pacific governments pursue sovereign production. South Korea’s Samsung Biologics signed USD 3.3 billion in contracts in 2024, and China’s Suzhou cluster scales single-use suites for domestic biosimilars. India’s Serum Institute uses disposable lines to meet WHO prequalification for African supply.

Middle East & Africa and South America nurture containerized facilities. WHO hubs in South Africa and Argentina rely on modular reactors, and Brazil’s Farmanguinhos uses single-use equipment to localize vaccine output. The United Arab Emirates’ biotech free-zones mirror these moves, signaling continued diffusion.

List of Companies Covered in this Report:

• ABEC
• Bioengineering
• Cellexus
• Celltainer
• CerCell
• Danaher
• Entegris
• Eppendorf
• Getinge
• Meissner Filtration
• Merck
• PBS Biotech
• Pierre Guérin
• Rentschler Biopharma
• Sartorius
• Solaris Biotech
• Thermo Fisher Scientific
• Univercells Technologies

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support